JP2007514639A - 少なくとも1の他の抗癌剤と組み合わせた少なくとも1のCdc25ホスファターゼ阻害剤を含有する製品 - Google Patents

少なくとも1の他の抗癌剤と組み合わせた少なくとも1のCdc25ホスファターゼ阻害剤を含有する製品 Download PDF

Info

Publication number
JP2007514639A
JP2007514639A JP2006516322A JP2006516322A JP2007514639A JP 2007514639 A JP2007514639 A JP 2007514639A JP 2006516322 A JP2006516322 A JP 2006516322A JP 2006516322 A JP2006516322 A JP 2006516322A JP 2007514639 A JP2007514639 A JP 2007514639A
Authority
JP
Japan
Prior art keywords
group
alkyl
amino
groups
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006516322A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007514639A5 (https=
Inventor
プレヴォー グレグワール
ブレザク パヌティエ マリークリスティーヌ
ディオレ クリスチャン
Original Assignee
ソシエテ ド コンセイユ ド ルシェルシェ エ ダアップリカーション シャンティフィック(エス.セー.エール.アー.エス.)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ソシエテ ド コンセイユ ド ルシェルシェ エ ダアップリカーション シャンティフィック(エス.セー.エール.アー.エス.) filed Critical ソシエテ ド コンセイユ ド ルシェルシェ エ ダアップリカーション シャンティフィック(エス.セー.エール.アー.エス.)
Publication of JP2007514639A publication Critical patent/JP2007514639A/ja
Publication of JP2007514639A5 publication Critical patent/JP2007514639A5/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2006516322A 2003-06-25 2004-06-24 少なくとも1の他の抗癌剤と組み合わせた少なくとも1のCdc25ホスファターゼ阻害剤を含有する製品 Pending JP2007514639A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0307649A FR2856688B1 (fr) 2003-06-25 2003-06-25 PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
PCT/FR2004/001586 WO2005000852A2 (fr) 2003-06-25 2004-06-24 Produit comprenant au moins un inhibiteur de phosphates cdc25 en association avec au moins un autre agent anti-cancereux

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009091214A Division JP2009149694A (ja) 2003-06-25 2009-04-03 少なくとも1の他の抗癌剤と組み合わせた少なくとも1のCdc25ホスファターゼ阻害剤を含有する製品

Publications (2)

Publication Number Publication Date
JP2007514639A true JP2007514639A (ja) 2007-06-07
JP2007514639A5 JP2007514639A5 (https=) 2007-08-09

Family

ID=33515382

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006516322A Pending JP2007514639A (ja) 2003-06-25 2004-06-24 少なくとも1の他の抗癌剤と組み合わせた少なくとも1のCdc25ホスファターゼ阻害剤を含有する製品
JP2009091214A Pending JP2009149694A (ja) 2003-06-25 2009-04-03 少なくとも1の他の抗癌剤と組み合わせた少なくとも1のCdc25ホスファターゼ阻害剤を含有する製品

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009091214A Pending JP2009149694A (ja) 2003-06-25 2009-04-03 少なくとも1の他の抗癌剤と組み合わせた少なくとも1のCdc25ホスファターゼ阻害剤を含有する製品

Country Status (14)

Country Link
US (3) US20060281736A1 (https=)
EP (3) EP1792905A1 (https=)
JP (2) JP2007514639A (https=)
AR (2) AR044930A1 (https=)
AT (1) ATE439836T1 (https=)
CA (1) CA2530668A1 (https=)
DE (1) DE602004022674D1 (https=)
DK (1) DK1641453T3 (https=)
ES (1) ES2332137T3 (https=)
FR (1) FR2856688B1 (https=)
MX (1) MXPA06000216A (https=)
MY (1) MY141725A (https=)
PL (1) PL1641453T3 (https=)
WO (1) WO2005000852A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2834289B1 (fr) * 2001-12-27 2004-03-19 Sod Conseils Rech Applic Derives de benzothiazole-4,7-diones et benzooxazole-4,7- diones, leur preparation et leurs applications therapeutiques
CN100425600C (zh) * 2001-12-27 2008-10-15 科学研究和应用咨询公司 苯并噻唑-和苯并唑-4,7-二酮衍生物及其作为cdc25磷酸酯酶抑制剂的用途
FR2856688B1 (fr) * 2003-06-25 2008-05-30 Sod Conseils Rech Applic PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
DE10353792A1 (de) 2003-11-13 2005-06-23 Exner, Heinrich, Dr.med.vet. Heil- und Wundsalbe auf der Basis einer wässrigen Emulsion
FR2877667B1 (fr) * 2004-11-05 2007-03-23 Sod Conseils Rech Applic Derives de 4,7-dioxobenzothiazole-2-carboxamides, leur preparation et leurs applications therapeutiques
FR2879598B1 (fr) * 2004-12-17 2007-03-30 Sod Conseils Rech Applic Inhibiteurs de phosphatases cdc25
FR2879460B1 (fr) * 2004-12-17 2007-02-23 Sod Conseils Rech Applic Associations anti-douleur comprenant un derive de dihydroimidazopyrazine
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
ES2366874T3 (es) * 2007-09-06 2011-10-26 Basf Se Mezclas de poliariléteres ramificados y polímeros hidrófilos.
WO2009100375A1 (en) 2008-02-06 2009-08-13 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
AR077463A1 (es) 2009-07-09 2011-08-31 Irm Llc Derivados de imidazo[1, 2 - a]pirazina y su uso en medicamentos para el tratamiento de enfermedades parasitarias
RS54648B1 (sr) * 2010-11-12 2016-08-31 Pharma Mar S.A. Kombinovana terapija sa antitumorskim alkaloidom
CN110691597A (zh) 2017-04-24 2020-01-14 诺华股份有限公司 2-氨基-1-(2-(4-氟苯基)-3-(4-氟苯基氨基)-8,8-二甲基-5,6-二氢咪唑并[1,2-a]吡嗪-7(8H)-基)乙酮及其组合的治疗方案
US20210106567A1 (en) * 2019-10-01 2021-04-15 United States Government As Represented By The Department Of Veterans Affairs Compositions and methods for inhibiting carp-1 binding to nemo
PE20252386A1 (es) 2019-11-21 2025-10-10 Pharma Mar Sa Metodo de tratamiento del cancer de pulmon de celulas pequenas con formulaciones de lurbinectedina
US11981645B1 (en) 2023-10-10 2024-05-14 King Faisal University N′-(2-naphthoyloxy)-2-(benzo[d]oxazol-2-yl)acetimidamide as antimicrobial compound

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001500838A (ja) * 1996-02-16 2001-01-23 バイオメジャー インコーポレイテッド ファルネシル トランスフェラーゼ阻害剤
WO2002009686A2 (fr) * 2000-07-28 2002-02-07 Societe De Conseils De Recherches Et D'applications Scientifique (S.C.R.A.S.) Inhibiteurs de phosphatases cdc25
WO2002096348A2 (fr) * 2001-05-30 2002-12-05 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Produit comprenant du mikanolide ou du dihydromikanolide en association avec un autre agent anti-cancereux

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US735674A (en) * 1902-01-29 1903-08-04 William C Matthias Sparking igniter for explosive-engines.
FR50000E (fr) 1938-11-29 1939-09-29 Moulin à café
US5523430A (en) * 1994-04-14 1996-06-04 Bristol-Myers Squibb Company Protein farnesyl transferase inhibitors
US6383871B1 (en) * 1999-08-31 2002-05-07 Micron Technology, Inc. Method of forming multiple oxide thicknesses for merged memory and logic applications
CZ20021550A3 (cs) * 1999-11-09 2003-02-12 Societe De Conseils De Recherches Et D'application Produkt zahrnující inhibitor transdukce signálů heterotrimerického G proteinu kombinovaný s jiným protirakovinným činidlem pro terapeutické použití v léčbě rakoviny
EP1345941A1 (fr) * 2000-12-20 2003-09-24 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3)
AR037714A1 (es) * 2001-12-06 2004-12-01 Maxia Pharmaceuticals Inc Derivados de tiazolidinona y oxazolidinona 2-sustituidos para la inhibicion de fosfatasas y el tratamiento de cancer
FR2834289B1 (fr) * 2001-12-27 2004-03-19 Sod Conseils Rech Applic Derives de benzothiazole-4,7-diones et benzooxazole-4,7- diones, leur preparation et leurs applications therapeutiques
CN100425600C (zh) * 2001-12-27 2008-10-15 科学研究和应用咨询公司 苯并噻唑-和苯并唑-4,7-二酮衍生物及其作为cdc25磷酸酯酶抑制剂的用途
FR2856688B1 (fr) * 2003-06-25 2008-05-30 Sod Conseils Rech Applic PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
FR2856686A1 (fr) * 2003-06-25 2004-12-31 Sod Conseils Rech Applic Benzothiazole-4,7-diones et benzooxazole-4,7-diones substituees en position 5 ou 6 et leurs procedes de preparation
JP4273056B2 (ja) * 2004-08-12 2009-06-03 不二越機械工業株式会社 研磨装置

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001500838A (ja) * 1996-02-16 2001-01-23 バイオメジャー インコーポレイテッド ファルネシル トランスフェラーゼ阻害剤
WO2002009686A2 (fr) * 2000-07-28 2002-02-07 Societe De Conseils De Recherches Et D'applications Scientifique (S.C.R.A.S.) Inhibiteurs de phosphatases cdc25
WO2002096348A2 (fr) * 2001-05-30 2002-12-05 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Produit comprenant du mikanolide ou du dihydromikanolide en association avec un autre agent anti-cancereux

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6010036602, Patrice Talagaa et al., "Synthesis of BOC−CYS−ALA−OME and its stereoselective addition to α−methylene−γ−butyrolactones", Tetrahedron, 1989, Volume 45, Issue 16, 5029−38 *
JPN7010001978, BAILLY,C., "Homocamptothecins: potent topoisomerase I inhibitors and promising anticancer drugs", Crit Rev Oncol Hematol, 2003, Vol.45, No.1, p.91−108 *
JPN7010001979, YU,C. et al, "The lethal effects of pharmacological cyclin−dependent kinase inhibitors in human leukemia cells pro", Cancer Res, 2003, Vol.63, No.8, p.1822−33 *
JPN7010001980, ZHU,X. et al, "Synthesis of S−linked glycopeptides in aqueous solution", J Org Chem, 2003, Vol.68, No.14, p.5641−51 *

Also Published As

Publication number Publication date
PL1641453T3 (pl) 2010-01-29
US20060281736A1 (en) 2006-12-14
WO2005000852A3 (fr) 2005-06-30
US20090253685A1 (en) 2009-10-08
DE602004022674D1 (de) 2009-10-01
EP2335702A1 (fr) 2011-06-22
MY141725A (en) 2010-06-15
ES2332137T3 (es) 2010-01-27
ATE439836T1 (de) 2009-09-15
FR2856688B1 (fr) 2008-05-30
DK1641453T3 (da) 2009-12-14
MXPA06000216A (es) 2006-04-11
FR2856688A1 (fr) 2004-12-31
CA2530668A1 (fr) 2005-01-06
AR070977A2 (es) 2010-05-19
EP1792905A1 (fr) 2007-06-06
US20090137596A1 (en) 2009-05-28
JP2009149694A (ja) 2009-07-09
EP1641453A2 (fr) 2006-04-05
EP1641453B1 (fr) 2009-08-19
WO2005000852A2 (fr) 2005-01-06
AR044930A1 (es) 2005-10-12

Similar Documents

Publication Publication Date Title
JP2009149694A (ja) 少なくとも1の他の抗癌剤と組み合わせた少なくとも1のCdc25ホスファターゼ阻害剤を含有する製品
AU2009231885B2 (en) Benzopyran and benzoxepin PI3K inhibitor compounds and methods of use
US20090131428A1 (en) Benzooxazole-4,7-dione, derivatives and their use as cdc25 phosphate inhibitors
US7495021B2 (en) Benzothiazole- and benzooxazole-4,7-dione, derivatives and their use as cdc25 phosphate inhibitors
US20100317658A1 (en) 4,7-Dioxobenzothiazole-2-Carboxamide Derivatives, Their Preparation And Their Therapeutic Uses
US7335674B2 (en) Benzothiazole-4,7-diones and benzoxazole-4,7-diones with substituents in position 5 or 6 and method for production thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070621

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070621

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100706

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101006

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20101006

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110106

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110201